Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: An observational trial

Liver International

Volumn 35, Issue 5, 2015, Pages 1607-1614

  Gevers, Tom J G ^a   Hol, Jeroen C ^a   Monshouwer, René ^a   Dekker, Helena M ^b   Wetzels, Jack F M ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Radbouumc ^*  (Netherlands)

Author keywords

ADPKD; Polycystic liver disease; Quality of life; Somatostatin analogues

Indexed keywords

ANALGESIC AGENT; ANGIOPEPTIN; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; PANCREAS ENZYME; CYCLOPEPTIDE; SOMATOSTATIN;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEPATIC CYST BLEEDING; HUMAN; HYPERGLYCEMIA; KIDNEY CYST INFECTION; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY PYELUM OBSTRUCTION; LIVER CYST INFECTION; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOOSE FECES; MALAISE; MALE; OBSERVATIONAL STUDY; OPEN STUDY; POSTPRANDIAL STATE; PYELONEPHRITIS; QUALITY OF LIFE; SIDE EFFECT; STEATORRHEA; TREATMENT DURATION; TREATMENT OUTCOME; URETER STENT; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; CYSTS; DRUG EFFECTS; KIDNEY; LIVER; LIVER DISEASES; MIDDLE AGED; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

ADULT; CYSTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; ORGAN SIZE; PEPTIDES, CYCLIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; QUALITY OF LIFE; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84927698457     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12726     Document Type: Article

References (32)

1. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.
2. Everson GT. Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc 1990; 65: 1020-5.
3. Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033-7.
4. van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum. Neth J Med 2011; 69: 367-71.
5. Wijnands TF, Neijenhuis MK, Kievit W, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014; 34: 1578-83.
6. Cnossen WRD, Drenth JPH. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis 2014; 9: 69.
7. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-30.
8. Gevers TJ, Drenth JP. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol 2011; 27: 294-300.
9. Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34: 702-13.
10. van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008; 57: 1338-9.
11. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-9.
12. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-61.
13. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-16.
14. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.
15. Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013: 382: 1485-95.
16. Gevers TJ, Inthout J, Caroli A, et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013; 145: 357-65. e1-2.
17. Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC Nephrol 2012; 13: 17.
18. Gigot JF, Jadoul P, Que F, et al., et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg 1997; 225: 286-94.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
20. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-12.
21. Bovenschen HJ, Janssen MJ, van Oijen MG, et al. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 2006; 51: 1509-15.
22. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
23. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-30.
24. Gines A, Salmeron JM, Gines P, et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992; 103: 1868-74.
25. Schmidt A, Pleiner J, Schaller G, et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int 2002; 61: 1788-93.
26. Vora JP, Owens DR, Ryder R, et al. Effect of somatostatin on renal function. Br Med J 1986; 292: 1701-2.
27. Meijer E, Drenth JP, d'Agnolo H, et al. Rationale and design of the DIPAK 1 Study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2014; 63: 446-55.
28. Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35: 266-74.
29. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest 2008; 31: 704-10.
30. Sallee M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1183-9.
31. Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-9.
32. Hateboer N, Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353: 103-7.